BriaCell Therapeutics Corp - Ordinary Shares - New
BCTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.41M
Close$
$1.41
54.3% downside
Current Fair Value
54.3% downsideOvervalued by 54.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $37.41 Million |
|---|---|
| Enterprise Value | $30.53 Million |
| Earnings per Share | $-6.97 |
| Beta | 1.52 |
| Outstanding Shares | 8,708,029 |
Return
| Return on Equity | -148.29% |
|---|---|
| Return on Assets | -128.23% |
| Return on Invested Capital | -130.04% |
Valuation & Multiples
| P/E Ratio | -0.33 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 6.71% |
|---|---|
| Total Invested | $189▼ 99.99% |
| Investors Holding | 2▼ 17.00% |
About BriaCell Therapeutics Corp
17 employees
CEO: William V. Williams
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.